In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported.
Anekpuritanang T, Klairmont MM, Gradowski J, Hagiwara K, Bailey NG, Chandra P, Liu Y, Mulder HL, Easton J, Zhang J, et al. Blood Adv. 2021 Dec 14; 5(23):5057-5059.